PierianDx: NGS Testing Simplified

Ted Briscoe, CEO
With the rise of modern gene sequencing technologies, today’s researchers are analyzing massive amounts of sequencing data to generate valuable clinical insights. By providing greater gene coverage, Next-Generation Sequencing (NGS) testing increases the chance of detecting rare mutations and offers cost-effective process for testing multiple genes.

“The sequencing of the human genome and the identification of links between specific genetic variants and diseases have led to great advances in patient treatment and the rise of more precise diagnoses and treatments,” says Ted Briscoe, CEO of PierianDx. “However, the increased use of NGS tests involves major challenges pertaining to managing scalability and handling the complexities of larger gene sets.”

In such a scenario, St. Louis, MO-based PierianDx provides a ‘one-space’ cloud-based solution that enables clinical labs to streamline their workflow and access a single, cloud workspace that provides a curated knowledgebase, comprehensive analysis, insightful interpretations, and precise reporting.

“PierianDx’s Clinical Genomicist Workspace™ (CGW) is a complete cloud-based suite of modules accompanied by support services that provide a data-driven ecosystem for clinical labs to launch or expand their NGS testing programs,” added Briscoe.

PierianDx generates a PDx Score™ with the help of a proprietary algorithm that helps determine the clinical relevance of individual variants in the context of a patient’s disease. Each score is produced through a computational process that mines PierianDx’s knowledgebase to associate the most relevant clinical information with the patient’s genetic data. The PierianDx knowledgebase leverages multiple databases to analyze and classify each detected variant so that the most clinically actionable results can be delivered.

“Our robust knowledgebase includes curated publications, biological information, computational predictions, population frequency data, clinical research and trial correlations, database reported disease variants, FDA drug labels and treatment guidelines, and PierianDx Partner Sharing Network content,” says Briscoe.

At the same time, the patient health information is stored in PierianDx’s private domain and the company employs well-established and accepted principles to ensure the protection and privacy of this information.


PierianDx’s Clinical Genomicist Workspace™ (CGW) is a complete cloud-based suite of modules accompanied by support services that provide a data-driven ecosystem for clinical labs to launch or expand their NGS testing programs


PierianDx has a scalable computational infrastructure that ensures that its customers’ patient cases are processed efficiently and rapidly, making the informatics, interpretation, and reporting processes a minimal component of the overall turnaround time. To ensure compliance, PierianDx manages its CGW software and knowledgebase on servers compliant with HIPAA and HITECH regulations and industry standards.

PierianDx’s customers includes from academic medical centers, cancer centers, health systems, children’s hospitals, and commercial labs. Each of its clients has a unique workflow established in their clinical lab, which needs to be adapted to handle the new challenges of genomic testing.

“Our support teams come from a clinical lab setting, so they understand the hurdles of incorporating a solution like CGW into the enterprise,” affirms Briscoe. “Also, we help our clients every step of the way, from implementation through initial test validation, to integration of genomic patient data into their Electronic Medical Record (EMR). The result is improved workflow and analysis, from DNA sequencing to a final clinically actionable report.”

Forging ahead, PierianDx will continue to expand its partner sharing network in the U.S. and other countries worldwide by building on its CGW platform.

“We are very fortunate to be in an industry where the results of our innovation can actually have an impact on patient lives,” concludes Briscoe. “With every implementation of CGW and each new member to our partner sharing network, we strive to accomplish better patient outcomes.”

Company
PierianDx

Headquarters
St. Louis, MO

Management
Ted Briscoe, CEO and Rakesh Nagarajan, Chief Biomedical Informatics Officer

Description
Enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA

PierianDx